Oral liquids
Solutions, syrups, suspensions, oral drops and oral sprays. Experience with paediatric liquids and herbal formulations.
ExploreCMO · CDMO · R&D
Manufacturing capabilities
Non-sterile dosage forms, formulation development and packaging pathways, matched to the product and its intended market.
Select the platform that fits your product
Topical & semisolid
Creams, ointments, gels, emulsions, dermal solutions and pharmaceutical soaps.
ExploreSprays & drops
Non-sterile nasal solutions and sprays, oral sprays and otic drops, within the relevant site and product-category scope.
ExploreSolid-form projects
Hard capsules; powders and effervescent powders in sachets. Tablet-production equipment is in procurement. Availability for plain, effervescent, lozenge or coated tablet projects is confirmed after installation, qualification and a review of the applicable site and product scope.
ExplorePackaging
Bottles, tubes, sachets, blisters and strips. Container compatibility, line fit and presentation are assessed together.
ExploreDevelopment & analytics
Formulation and reformulation, analytical development, stability programmes, pilot support and technical documentation coordinated with the client’s regulatory team.
ExploreDevelopment questions worth defining early
Reformulation, solubility & dissolution
Discuss a new dosage-form concept or a defined formulation challenge. We assess the existing evidence, analytical needs and feasibility before agreeing a development programme. Bioavailability and product performance require project-specific evidence.
Paediatric & orphan-medicine enquiries
Share the intended population, dose presentation, excipient constraints and forecast volume. We assess dosage-form fit, batch scale and site readiness within the applicable authorised scope.
Product categories
Pharmaceuticals for human use, including investigational products; food supplements; cosmetics; and medical devices within the authorised scope. FSMP development requests are assessed separately against the applicable product, manufacturing and regulatory requirements.
The Site 1 authorisation specifically lists nasal sprays for medical devices. A broader device claim is assessed separately; product-specific readiness is confirmed before quotation.
A European base for your next complex programme.
EUROPEAN CMO / CDMO · NEARSHORING
Nearshoring for complex molecules and biotechnology startups: from formulation and technology-transfer assessment to an agreed non-sterile manufacturing programme in Athens.
See our development approach
EIREN and Firmie are being developed by Sikalias Pharmaceutical Laboratories. They are not yet available for sale and no launch date has been announced.
EIREN & Firmie · R&D ↗